Identifying a novel mechanism of L-leucine uptake in Mycobacterium tuberculosis using a chemical genomic approach
eLife · 2026
DOI: 10.7554/elife.107025 ↗Kurz gefasst
Fachartikel in der Zeitschrift eLife, 2026. Verfasst von Nisheeth Agarwal und 7 weiteren Autor:innen. Beteiligte Einrichtung: Translational Health Science and Technology Institute, NCR Biotech Science Cluster, Faridabad, India. Hauptthemen laut MEDLINE: Mycobacterium tuberculosis, Leucine, Antitubercular Agents. Die Arbeit nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Council of Scientific and Industrial Research (CSIR), Department of Science and Technology, Govt. of India, Science and Engineering Research Board, Department of Science and Technology, Govt. of India.
Abstract (Originalsprache)
Amino acid biosynthesis is vital for Mycobacterium tuberculosis (Mtb) proliferation and tuberculosis (TB) pathogenesis. However, it is not clear how amino acids are transported in Mtb, particularly the branched-chain amino acids (BCAAs) that contribute to the production of the cell-wall lipid component precursors, such as acetyl-CoA and propionyl-CoA. While performing the screening of an FDA-approved repurposed library of small molecule inhibitors against the auxotrophic strain Mtb mc 2 6206, which lacks leuC-leuD and panC-panD genes, we identified a molecule, namely semapimod, which exclusively inhibits the growth of the auxotrophic strain, whereas no effect is observed against the wild-type Mtb H 37 Rv. Interestingly, 24 hr of exposure of Mtb mc 2 6206 to semapimod causes massive transcriptional reprogramming with differential expression of >450 genes associated with a myriad of metabolic activities. By performing a series of experiments, we affirm that semapimod indeed inhibits the L-leucine uptake in Mtb mc 2 6206 by targeting a protein involved in the cell-wall lipid biosynthesis pathway. Remarkably, semapimod treatment of mice infected with Mtb H 37 Rv causes a significant reduction of bacterial load in lungs and spleen, despite showing no efficacy against the pathogenic strain in vitro. Overall findings of our study reveal that together with an endogenous pathway for L-leucine biosynthesis, a well-orchestrated machinery for its uptake is functional in Mtb, which is important for intracellular survival of the TB pathogen.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Translational Health Science and Technology Institute, NCR Biotech Science Cluster, Faridabad, India.
- National Institute of Animal Biotechnology (NIAB), Hyderabad, India.
ORCID-Profile: Nisheeth Agarwal, Himanshu Gogoi, Eeba, Linus Augustin, Mohd Younus Khan, Sayan Kumar Bhowmick, Bappaditya Dey
Förderung
- Council of Scientific and Industrial Research (CSIR), Department of Science and Technology, Govt. of India
- Science and Engineering Research Board, Department of Science and Technology, Govt. of India
Zitieren
APA
Agarwal, N., Gogoi, H., Eeba, Augustin, L., Khan, M. Y., Kumar, Y., Bhowmick, S. K., & Dey, B. (2026). Identifying a novel mechanism of L-leucine uptake in Mycobacterium tuberculosis using a chemical genomic approach. eLife. https://doi.org/10.7554/elife.107025
Vancouver
Agarwal N, Gogoi H, Eeba, Augustin L, Khan MY, Kumar Y, et al. Identifying a novel mechanism of L-leucine uptake in Mycobacterium tuberculosis using a chemical genomic approach. eLife. 2026. doi:10.7554/elife.107025
BibTeX
@article{Agarwal2026,
author = {Agarwal, Nisheeth and Gogoi, Himanshu and Eeba and Augustin, Linus and Khan, Mohd Younus and Kumar, Yashwant and Bhowmick, Sayan Kumar and Dey, Bappaditya},
title = {Identifying a novel mechanism of L-leucine uptake in Mycobacterium tuberculosis using a chemical genomic approach},
journal = {eLife},
year = {2026},
doi = {10.7554/elife.107025}
}
EUVIMED